Aligos Therapeutics announced six preclinical presentations, including three oral presentations, at the 2025 International HBV Meeting. These presentations highlight the company's ongoing innovation in liver and viral diseases. New data will be presented on the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting.
These preclinical findings corroborate the clinical observations of HBV antigen reductions seen in patients treated with ALG-000184 monotherapy. This data directly indicates that ALG-000184 can activate the secondary mechanism of CAM-Es. This further strengthens the understanding of its potential as a best-in-class therapy for chronic HBV infection.
Additionally, Aligos will present its discovery stage antisense oligonucleotide (ASO) program for the treatment of Hepatitis Delta Virus (HDV) infection. This novel ASO approach uniquely targets the destruction of the viral genome, positioning it as a potential cure for HDV, which often leads to more rapid disease progression when co-infected with HBV.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.